No Data
No Data
Form 144 | Biomarin Pharmaceutical(BMRN.US) Officer Proposes to Sell 2.17 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 28, $Biomarin Pharmaceutical(BMRN.US)$ Officer Davis George Eric intends to sell 24,602 shares of its common stock on Mar 28, with a total market value of approximately $2.
Analysts' Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)
BioMarin Pharmaceutical's Voxzogo Opportunities Being Underappreciated -- Market Talk
1534 ET - UBS believes expansion opportunities for BioMarin's Voxzogo could potentially bring in around $3 billion to $4 billion in revenue. The drug is currently used to treat achondroplasia, a genet
Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness
In the last year, many BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Buy Rating Justified by Voxzogo's Efficacy in Hypochondroplasia Treatment: A Deep Dive Into BioMarin Pharmaceutical's Clinical Data
No Data